RT Journal Article
SR Electronic
T1 Modelling vaccination capacity at mass vaccination hubs and general practice clinics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.07.21255067
DO 10.1101/2021.04.07.21255067
A1 Hanly, Mark
A1 Churches, Tim
A1 Fitzgerald, Oisín
A1 Caterson, Ian
A1 MacIntyre, Chandini Raina
A1 Jorm, Louisa
YR 2021
UL http://medrxiv.org/content/early/2021/04/07/2021.04.07.21255067.abstract
AB COVID-19 population vaccination programs are underway globally. In Australia, the federal government has entered into three agreements for the supply of vaccines, with roll-out beginning for the highest priority groups in February 2021. Expansion of the vaccination program throughout February and March failed to meet government targets and this has been attributed to international supply issues. However, Australia has local capacity to manufacture one million doses of the AstraZeneca vaccine weekly and once fully operational this will greatly increase the national vaccination capacity. Under current plans, these vaccine doses will be distributed primarily through a network of general practices, to be joined in later phases by community pharmacies. It remains unclear whether these small distribution venues have the logistical capacity to administer vaccines at the rate they will become available. To inform this discussion, we applied stochastic queue network models to estimate the capacity of vaccination sites based on assumptions about appointment schedules, service times and available staff numbers. We specified distinct queueing models for two delivery modes: (i) mass vaccination hubs located in hospitals or sports arenas and (ii) smaller clinics situated in general practices or community pharmacies. Based on our assumed service times, the potential daily throughput for an eight hour clinic at a mass vaccination hub ranged from around 500 vaccinations for a relatively small hub to 1,400 vaccinations a day for a relatively large hub. For GP vaccination clinics, the estimated daily throughput ranged from about 100 vaccinations a day for a relatively small practice to almost 300 a day for a relatively large practice. Stress tests showed that for both delivery modes, sites with higher staff numbers were more robust to system pressures, such as increased arrivals or staff absences, and mass vaccination sites were more robust that GP clinics. Our analysis is accompanied by an interactive web-based queue simulation applet, which allows users to explore queue performance under their own assumptions regarding appointments, service times and staff availability. Different vaccine delivery modes offer distinct benefits and may be particularly appealing to specific population segments. A combination of expanded mass vaccination hubs and expanded GP vaccination is likely to achieve mass vaccination faster than either mode alone.Competing Interest StatementMark Hanly receives funding from the National Health and Medical Research Council (NHMRC) and the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE). Timothy Churches receives funding from the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE), Australian Research Data Commons (ARDC), UNSW Sydney and the Ingham Institute for Applied Medical Research. Oisin Fitzgerald receives funding from the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE). C Raina MacIntyre receives funding from Medical Research Futures Fund and NHMRC. She has consulted for Astra Zeneca and Janssen on COVID-19 vaccines and been on an advisory board for Seqirus on COVID-19 vaccines. In the past she has been on advisory boards and had support from vaccine manufacturers Sanofi, Seqirus, Merck, Pfizer, GSK, Bavarian Nordic and Emergent Biosolutions for other vaccines. Louisa Jorm receives funding from the Medical Research Futures Fund, Australian Research Data Commons, NHMRC, UNSW Sydney and the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE).Funding StatementThis research was supported by the generous assistance of Ian Sharp, philanthropic supporter of UNSW research, and by a research seed grant provided by the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE) Infectious diseases, Immunity and Inflammation (Triple-I) Clinical Academic Group.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UNSW Human Research Ethics Committee (Neglibible Risk Research)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode and data are available in the GitHub repository at https://github.com/CBDRH/vaccineQueue https://github.com/CBDRH/vaccineQueue https://cbdrh.shinyapps.io/queueSim/